Based on these findings, we revealed that both GOLPH3 and YB-1 may be promising molecular targets for new therapeutic cancer strategies during the treatment of both androgen-dependent PC and castration-resistant PC. The gene discussed is GOLPH3; the disease is pachyonychia congenita.